Processa Pharmaceuticals, Inc. · NASDAQ:PCSA

Processa Pharmaceuticals — Investor Presentation (September 2026)

15 slides from Processa Pharmaceuticals's investor presentation, September 2026

  1. Slide 1: Company Overview

    Company Overview September 2026 Vidya Therapeutics is a subsidiary of Process Pharmaceuticals, Inc.

  2. Slide 2: Disclaimers

    Disclaimers The information in this Presentation has been prepared by Processa Pharmaceuticals, Inc. ("Processa"), including its subsidiary Vidya Therapeutics, Inc. ("Vidya" and, together with Processa and each of Processa's subsidiaries, the "combined company") and contains information pertaining t

  3. Slide 3: Processa merger with Vidya focused on advancing lead program VT-7208, pipeline-in-a-product

    Processa merger with Vidya focused on advancing lead program VT-7208, pipeline-in-a-product OVERVIEW • Definitive merger agreement for a stock-for-stock transaction • Vidya’s outstanding equity interests exchanged for a combination of shares of Processa common stock and newly created Series A non-vo

  4. Slide 4: VT-7208 pipeline-in-a-product provides optionality from a single optimized molecule

    VT-7208 pipeline-in-a-product provides optionality from a single optimized molecule VT-7208 is a potentially best-in-class, oral, once-daily BTK inhibitor for immune-mediated disease P OT E N T IA L P ROG R A M PHASE 1 PHASE 2 PHASE 3 IN D ICAT ION S VT-7208 is engineered Food allergy to improve on

  5. Slide 5: VT-7208 expected to provide multiple value creation paths

    VT-7208 expected to provide multiple value creation paths CLINICALLY VALIDATED INDICATION EXPANSION CLEAR UNMET NEED / MECHANISM POTENTIAL LARGE ADDRESSABLE MARKETS • BTK inhibition established across Parallel development in CSU, food CSU: >1.7M U.S. patients1 autoimmune diseases allergy and relapsi

  6. Slide 6: BTK is a compelling target

    BTK is a compelling target BTK offers the potential to modulate both adaptive and innate immune pathways with a single molecule CENTRAL IMMUNE B-CELLS (ADAPTIVE) MYELOID CELLS (INNATE) SIGNALING NODE BCR FcR BCR signaling drives BTK’s dual role FcR signaling drives • Proliferation • Links adaptive a

  7. Slide 7: Strong and differentiated preclinical profile supports advancement into the clinic

    Strong and differentiated preclinical profile supports advancement into the clinic Strong CNS • Potent in vitro and in vivo with strong Penetration peripheral and CNS target engagement • Consistent efficacy observed across disease models • Clean metabolic profile with predictable PK VT7208 • Low liv

  8. Slide 8: VT-7208 Phase 1 study design enabled efficient dose escalation and translational readouts

    VT-7208 Phase 1 study design enabled efficient dose escalation and translational readouts; currently advancing Phase 2 POC SINGLE ASCENDING DOSE MULTIPLE ASCENDING DOSE 60 mg 10 mg QD x 7d SAFETY SRC >95% BTK TO SRC 20 mg 20 mg QD x 7d x 24 hrs Food Effect 5 mg Cohort 20 mg 6 VT-7208:2 PBO per cohor

  9. Slide 9: VT-7208's Phase 1 results demonstrated favorable safety profile and tolerability profile

    VT-7208’s Phase 1 results demonstrated favorable safety profile and tolerability profile PARAMETER SAD FOOD COHORT MAD (QDX7) 5 mg 20 mg 60 mg 20 mg 10 mg 20 mg SAEs 0/6 0/6 0/6 0/8 0/6 0/6 1/6 Grade 3 or higher 0/6 0/6 0/6 0/8 0/6 Blood draw site pain 1/6 1/8 Related AEs 0/6 0/6 0/6 0/6 Headache (G

  10. Slide 10: VT-7208's predictable PK supports low, once-daily oral dosing

    VT-7208’s predictable PK supports low, once-daily oral dosing SINGLE ASCENDING DOSE MULTIPLE ASCENDING DOSE CSF IC50 Human derived iPSC derived microglia 5 mg 10 mg 20 mg 60 mg 10 mg 20 mg • Predictable PK profile, consistent with preclinical characterization • Near dose-proportional increases in ex

  11. Slide 11: VT-7208 demonstrated robust and sustained BTK target engagement at ≥ 5 mg/day

    VT-7208 demonstrated robust and sustained BTK target engagement at ≥ 5 mg/day SINGLE ASCENDING DOSE MULTIPLE ASCENDING DOSE Near complete target occupancy sustained for 24 hours 100% BTK occupancy at steady state; confirmed by across doses phospho-BTK signaling assays ≥95% occupancy sustained up to

  12. Slide 12: Robust and sustained inhibition of pBTK demonstrated modulation of signaling pathway

    Robust and sustained inhibition of pBTK demonstrated modulation of signaling pathway • MAD cohort results • SAD cohort underway Placebo 10 mg 20 mg The sustained inhibition of pBTK demonstrated the potential for durable pharmacodynamic activity, reinforcing confidence in the molecule’s therapeutic a

  13. Slide 13: Phase 1 complete, advancing Phase 2 POC studies in Food Allergy, CSU, & Relapsing MS

    Phase 1 complete, advancing Phase 2 POC studies in Food Allergy, CSU, & Relapsing MS with data expected in 2027 and 2028 TARGET / ASSET PRECLINICAL TRANSLATIONAL CLINICAL STRATEGIC  Validated biology  Low risk of  Predictable PK  Well-defined PoC  Capital-efficient hepatotoxicity supporting onc

  14. Slide 14: VT-7208 pipeline-in-a-product provides optionality from a single optimized molecule

    VT-7208 pipeline-in-a-product provides optionality from a single optimized molecule VT-7208 is a potentially best-in-class, oral, once-daily BTK inhibitor for immune-mediated disease P OT E N T IA L P ROG R A M PHASE 1 PHASE 2 PHASE 3 IN D ICAT ION S VT-7208 is engineered Food allergy to improve on

  15. Slide 15: Vidya Therapeutics is a subsidiary of Process Pharmaceuticals, Inc.

    Vidya Therapeutics is a subsidiary of Process Pharmaceuticals, Inc.

Processa Pharmaceuticals — Investor Presentation (September 2026) on 6ix